Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,797 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Tumors Clear all
Completed Phase 1 Interventional

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

NCT00001383
View directory record Official record
Conditions
Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma, Ovarian Cancer
Interventions
PSC 833, paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

NCT01235962
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Cancer
Interventions
pazopanib, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
69
States / cities
Jonesboro, Arkansas • Antioch, California • Beverly Hills, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 16, 2026, 1:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer

NCT00093405
View directory record Official record
Conditions
Kidney Cancer
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 16, 2026, 1:45 AM EDT
Terminated Not applicable Interventional Results available

PET/MR Characterization of Renal Cell Carcinomas

NCT04271254
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
PET/MR
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 16, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710
View directory record Official record
Conditions
Tumor
Interventions
ipilimumab, nivolumab, ENHANZE (rHuPH20)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

NCT02639182
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
AGS-16C3F, Axitinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

NCT02437370
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma
Interventions
Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

NCT00001570
View directory record Official record
Conditions
Kidney Neoplasms, Neoplasm Metastasis
Interventions
PSC 833, vinblastine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 1:45 AM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07195682
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
BMS-986506, Pumitamig, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 1:45 AM EDT
Terminated Phase 4 Interventional

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

NCT00352859
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon, Gemcitabine or Interferon (only)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 16, 2026, 1:45 AM EDT
Not listed Phase 2 Interventional

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

NCT00003181
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, sargramostim, vinblastine sulfate
Biological · Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 16, 2026, 1:45 AM EDT
Terminated No phase listed Observational

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00957736
View directory record Official record
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer

NCT00077129
View directory record Official record
Conditions
Kidney Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
35
States / cities
Jacksonville, Florida • Aurora, Illinois • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

NCT01034631
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Everolimus, BNC105P
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
94
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Burbank, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 16, 2026, 1:45 AM EDT
Active, not recruiting No phase listed Observational

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

NCT03291028
View directory record Official record
Conditions
Renal Cell Carcinoma, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer, Urethral Cancer
Interventions
Immune checkpoint inhibitor targeting PD1
Biological
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 16, 2026, 1:45 AM EDT
Suspended Phase 2 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

NCT03575611
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 16, 2026, 1:45 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Interventions
KFA115, pembrolizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

NCT00002914
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
piritrexim
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
28
States / cities
Atlanta, Georgia • Decatur, Georgia • Chicago, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 16, 2026, 1:45 AM EDT
Recruiting Phase 1 Interventional

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

NCT07062549
View directory record Official record
Conditions
Renal Cell Carcinoma (Kidney Cancer)
Interventions
111In-XYIMSR-01
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Ask Questions (ASQ):Implementation of a Communication Intervention

NCT05025748
View directory record Official record
Conditions
Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage II Cervical Cancer, Stage III Cervical Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Stage II Kidney Cancer, Stage III Kidney Cancer, Stage IV Kidney Cancer
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 16, 2026, 1:45 AM EDT
Recruiting Phase 2 Interventional

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
XL092, Nivolumab
Drug
Lead sponsor
Karie Runcie
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 1:45 AM EDT